Sonrai Analytics
Sonrai Analytics is a Belfast-based precision medicine company that uses its Sonrai Discovery platform to integrate multi-modal biomedical data with AI/ML workflows inside a secure Trusted Research Environment, serving pharmaceutical and biotech clients including Roche, Candel Therapeutics, and NHS.
- Company typePrivate
- Founded2018
- HeadquartersBelfast, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Sonrai Analytics does
Sonrai Analytics is a Belfast-based precision medicine analytics company founded in 2018 by Dr Darragh McArt and Dr Deva Senevirathne. It operates an AI-powered multi-modal data analytics platform called Sonrai Discovery that integrates genomic, proteomic, imaging, and clinical data inside a secure Trusted Research Environment (TRE). The platform uses machine learning techniques including XGBoost, t-SNE, MOFA, and UMAP for dimensionality reduction, clustering, and classification, with published performance of 94% sensitivity, 89% specificity, and AUC-ROC of 0.93 on early cancer detection models built with AWS SageMaker.
The company delivers its capabilities through three decision modules — Translational Analytics, Target ID & Validation, and Patient Stratification — that span the drug development lifecycle from preclinical research through clinical trials. Its primary customers are pharmaceutical and biotech companies including Roche, Candel Therapeutics, AOA Dx, and Plectonic Biotech, alongside institutional users such as NHS and Cancer Research UK.
Sonrai monetizes through a combination of platform subscriptions and professional services in which its scientists work alongside client R&D teams to analyze datasets and produce decision-ready translational evidence. Go-to-market is enterprise field sales with consultative 'Book Demo' CTAs, supplemented by a flagship global strategic partnership with SmartLabs (announced August 2025) that provides distribution into SmartLabs' network of five managed research centers. The company has raised approximately £2.175M in seed-plus funding plus undisclosed rounds from Eckuity (2022) and Beach Equity (2025), and operates from Belfast with expansion into US and EU markets.
Sonrai Analytics firmographics
Firmographics- Name
- Sonrai Analytics
- Legal name
- Sonrai Analytics
- Website
- https://sonraianalytics.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sonrai Analytics is a Belfast-based precision medicine company that uses its Sonrai Discovery platform to integrate multi-modal biomedical data with AI/ML workflows inside a secure Trusted Research Environment, serving pharmaceutical and biotech clients including Roche, Candel Therapeutics, and NHS.
- Ownership category
- akta.pro rank
Sonrai Analytics industry classification
Industry- Product category
- Precision Medicine Analytics Software
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Computer Processing & Data Preparation (7374), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Sonrai Analytics is headquartered
LocationHeadquarters
- HQ city
- Belfast
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Sonrai Analytics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Analytics Platform and Services: AI-powered data analytics platform and scientific analysis services for pharma and biotech companies to discover biomarkers, stratify patients, and support clinical trial decisions
- Professional Services: Scientific expertise and consulting services where Sonrai scientists work alongside client R&D teams to analyze datasets and deliver translational evidence
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Sonrai Analytics product offering
Product offeringCore offering
Sonrai Analytics operates Sonrai Discovery, a cloud-native AI-powered analytics platform that integrates multi-modal biomedical data (genomic, proteomic, imaging, and clinical) within a secure Trusted Research Environment (TRE) to enable biomarker discovery, patient stratification, and translational analysis for precision medicine teams. The company combines the platform with scientific services where Sonrai scientists work alongside client R&D teams to deliver decision-ready evidence from complex biomedical datasets.
Product overview
Sonrai Analytics offers a unified AI-powered precision medicine analytics platform called Sonrai Discovery, which is supplemented by three core decision modules: Translational Analytics, Target ID & Validation, and Patient Stratification. The platform integrates multi-modal biomedical data (genomic, proteomic, imaging, and clinical) within a secure, governed Trusted Research Environment to generate decision-ready evidence for biomarker discovery, patient stratification, and drug development programs.
Differentiator
Problem solved
Functional benefit
Brands
- Sonrai Discovery: AI-powered analytics platform for precision medicine biomarker discovery, data integration, and analysis within a secure, governed research environment.
Products and services
- Sonrai Discovery Platform Cloud-native AI analytics platform that serves as the foundation for all Sonrai services. Provides a secure Trusted Research Environment (TRE) with reproducible workflows, multi-modal data integration (genomic, proteomic, imaging, clinical), and AI-assisted exploration capabilities for biomarker discovery, patient stratification, and translational analysis. Designed for pharmaceutical, biotechnology, and translational research organizations.
- Multi-Omics Data Analysis Services
Quantifiable outcome
- 94% sensitivity, 89% specificity, AUC-ROC of 0.93 for early cancer detection models
- +8 more outcomes
Companies that use Sonrai Analytics
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles2 records
Sonrai Analytics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
Sonrai Analytics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and flagship.
- SmartLabscoreSmartLabs partnered with Sonrai to integrate AI analytics into its network of research centers. The collaboration aims to accelerate biomarker discovery and diagnostic workflows for biotech and pharmaceutical companies by offering Sonrai's AI platform Sonrai Discovery.
- SmartLabsflagshipSmartLabs and Sonrai Analytics announced a global strategic partnership to integrate Sonrai's AI analytics platform Sonrai Discovery into SmartLabs' network of five managed research centers, exclusively available to SmartLabs' member companies. Both companies will jointly develop bespoke AI applications and laboratory informatics tools combining experimental and infrastructure data to predict scientific outcomes and accelerate discovery.
- Plectonic BiotechcoreSonrai and Plectonic Biotech joined forces to advance precision immunotherapies for cancer through combined AI analytics and immunotherapy development expertise.
- AOA DxcoreUK-based AI and data analytics firm Sonrai partnered with US biotechnology company AOA Dx to develop a serum-based multi-omic liquid biopsy test for early ovarian cancer detection. The partnership combines artificial intelligence with multi-omics approaches to improve diagnostic accuracy and patient outcomes.
- AWS (Amazon Web Services)coreSonrai partnered with AWS to build an MLOps framework using Amazon SageMaker AI for precision medicine biomarker discovery. The solution processed over 8,000 potential biomarkers across proteomics, metabolomics, and lipidomics modalities, generating 15 models with top performer achieving 94% sensitivity, 89% specificity, and AUC-ROC of 0.93 for early cancer detection.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Sonrai Analytics competitors and assessment
Company assessmentBroad incumbents
- Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab biology with AI-driven phenomics and multi-omic analysis to identify targets and biomarkers, operating in adjacent territory to Sonrai's target ID and biomarker discovery work.
- Tempus Labs: Tempus is a large-scale precision medicine platform combining multi-omic sequencing, imaging AI, and a TRE-style research environment for pharma, targeting the same biopharma buyers as Sonrai but with much broader data assets and capital base.
- Schrödinger: Schrödinger provides computational biology and physics-based modeling software widely adopted in pharma R&D, overlapping with Sonrai's decision modules for target prioritization and translational evidence generation.
- Exscientia: Exscientia applies AI-driven precision medicine, including patient stratification and biomarker-guided clinical trials for pharma partners, closely tracking Sonrai's translational analytics and patient stratification modules.
- Ginkgo Bioworks: Ginkgo Bioworks provides large-scale biological engineering and multi-omic data infrastructure used by pharma and biotech, addressing adjacent target ID, biomarker discovery, and synthetic biology analytics needs.
Direct peers
- Owkin: Owkin applies federated AI to multi-omic and imaging data for pharma R&D and clinical trials, directly overlapping Sonrai's biomarker discovery, patient stratification, and translational analysis use cases for biopharma.
- Insitro: Insitro builds AI/ML models on multi-modal biological data (genomics, imaging, clinical) to accelerate drug discovery, mirroring Sonrai's data integration and predictive modeling approach for pharma pipelines.
- BenevolentAI: BenevolentAI uses AI on multi-modal biomedical data to discover targets and biomarkers for pharma R&D, comparable to Sonrai's target ID/validation and biomarker discovery offerings.
- PathAI: PathAI applies AI to digital pathology and integrates pathology findings with molecular/clinical data for biomarker discovery, directly comparable to Sonrai's H&E/IHC imaging AI and multimodal analytics capabilities.
Emerging players
- Aignostics: Aignostics is an emerging AI digital pathology platform serving pharma biomarker programs, overlapping with Sonrai's computational pathology and multimodal biomarker discovery workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Sonrai Analytics social profiles
Digital presenceSonrai Analytics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sonrai Analytics leadership team
Management profileNumber of profiles
Profiles8 records
Sonrai Analytics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sonrai Analytics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sonrai Analytics
What does Sonrai Analytics do?
Sonrai Analytics operates Sonrai Discovery, a cloud-native AI-powered analytics platform that integrates multi-modal biomedical data (genomic, proteomic, imaging, and clinical) within a secure Trusted Research Environment (TRE) to enable biomarker discovery, patient stratification, and translational analysis for precision medicine teams. The company combines the platform with scientific services where Sonrai scientists work alongside client R&D teams to deliver decision-ready evidence from complex biomedical datasets.
Is Sonrai Analytics a public or private company?
Sonrai Analytics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sonrai Analytics founded?
Sonrai Analytics was founded in 2018. It employs 11 to 50 people.
Where is Sonrai Analytics based?
Sonrai Analytics is headquartered in Belfast, United Kingdom, in the Europe region.
How does Sonrai Analytics make money?
Two revenue lines are on record. Analytics Platform and Services are the primary driver. The others are professional Services.
Who are Sonrai Analytics's main competitors?
Broad incumbents on record are Recursion Pharmaceuticals, Tempus Labs, Schrödinger, Exscientia and Ginkgo Bioworks. Direct peers are Owkin, Insitro, BenevolentAI and PathAI. Aignostics is listed as an emerging player.
Does Sonrai Analytics have an API?
No public API is recorded for Sonrai Analytics.
What industry is Sonrai Analytics in?
Sonrai Analytics's product category is Precision Medicine Analytics Software. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 54171 and its SIC code is 8731.